Prime Medicine
Naqi Haider has a diverse work experience spanning several companies and roles. Naqi is currently working at Prime Medicine, Inc. as the Associate Director and Head of Stem Cell Biology, a position they have held since February 2023. Prior to this, they worked at Editas Medicine, where they started as a Senior Research Associate in Ophthalmology (Gene Therapy/Stem Cells) from March 2019 to July 2020, and later became a Principal Research Associate in Discovery Biology from July 2020 to April 2021.
Before joining Editas Medicine, Naqi worked at the University of Pennsylvania as a Research Specialist from January 2015 to March 2019, and concurrently held the position of Fellow at The Penn Center for Innovation from December 2016 to December 2018. Naqi also had a role as a Technology Transfer Consultant at New York Blood Center from June 2015 to January 2016.
Other previous experiences include being an Adjunct Professor at Dominican College of Blauvelt from August 2013 to July 2015, and working as a Researcher for a Masters degree at Mount Sinai Health System from January 2010 to June 2012.
Naqi Haider obtained a Bachelor's degree in Biotechnology from the Rochester Institute of Technology. Following this, they pursued a Master's degree in Neuroscience at the Icahn School of Medicine at Mount Sinai. Later, they attended the University of Pennsylvania and completed a Master of Law degree in Intellectual Property Law. In January 2016, Naqi Haider obtained a certification in Intellectual Property Law and Policy from the University of Pennsylvania through edX.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.